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RE ETINOBLASTOMA (RB)
For use in the RNase protection assay, we produced short subclones of 4.7R (Fig. 1) (474) (579) make the probes, the 4.7R cDNA 23H was cleaved at the internal Eco RI (163) 300 bp site into 3652-bp (3') and 834-bp (5') fragments. These were subcloned into Bluescript SK (Stratagene) and pTZ18R (Pharmacia) plasmid vectors, respectively. Overlapping plasmids were generated either by unidirectional deletion (26) of the 3' end, or by digestion with the appropriate restriction endonucleases and religation. The ends of all subclones were determined by dideoxy sequencing (27) and the lengths were deduced from the published sequence (9). Radioactively labeled RNA probes were synthesized from linearized plasmid DNA with phage T7 or T3 RNA polymerase as described (6). single base pair mismatches at the site of cleavage (Fig. 2, A and B) . In tumor RB412, the site of cleavage mapped approximately to nucleotide 2655 and in tumor RB543 to nucleotide 1890 of the sequence published by Lee et al. (9) . Hybridization with restriction fragment length polymorphic (RFLP) DNA probes (1, 11, 12) indicated that RB1 in these tumors had reduced to homozygosity (1, 13). The mutations were detected only in the tumors and not in the lymphocytes of either patient.
Three of the five tumors (RB247, RB405, and RB462) exhibited identical RNase cleavage patterns with the overlapping probes 11H, 12H (Fig. 2C), and 23H  (Fig. 3) . The small 23H probe (163 bp) protected both a fill-length and a 111-bp fragment in each tumor, locating the abnormality in each of the three tumors precisely 52 bp from the 5' end of the probe (Figs. 1  and 3 ). In none of the three tumors was the expected 52-bp 5' fragment of 23H detected. In each tumor a filly protected band of 163 bp was also evident in addition to the 11 1-bp band, indicating either the presence of transcripts from the other allele or incomplete digestion of the RNA hybrids protected by the mutant allele. The possibility that these identical mutations were derived from a common origin was eliminated both by the results of RFLP analysis of tumor and constitutional DNAs with a highly polymorphic DNA probe (14) and by analysis of their family histories, which indicated that the patients were unrelated.
Because patient 247 had bilateral RB, unaffected parents, and two unaffected siblings, it was likely that this child had a new germline abnormality of the RB1 gene, which arose in the germ cells of one parent or early in the embryo. This prediction was confirmed by the observation that lymphocytes of the child (EBV247) showed the same mutation as the tumor (Fig. 2C) ; lymphocytes from both parents did not show the mutation. Patient 462 had bilateral RB, inherited from his affected father. The mutation detected in the tumor RB462, however, was evident neither in the patient's fibroblasts (F462) nor in the father's lymphocytes (EBV468) (Fig. 3) . Patient 405 had unilateral RB, no family history of RB, and, as expected, the mutation was not detected in his lymphocytes (Fig. 2C ).
AU RNA was prepared by the guanidinium isothiocyanate method as described (28) . Constitutional RNA was isolated from EBV-transformed lymphoblastoid cell lines (EBV) (10) or conconavalin A-stimulated lymphocytes (L). RNA probes were hybridized to total cellular RNA and digested with RNase A (5 pFg/lm) and Ti (100 U/ml) as described (6). Protected fragments were analyzed by denaturing polyacrylamide gel electrophoresis followed by autoradiography. unequivocally identified, it is possible that one or more 5' exons remain to be discovered. Another, but less likely, explanation of the clustering of RNA deletions at the 5' end is that the mutations in these three patients lead to a stable secondary RNA structure, such as a stem loop, so that the mutated mRNA cannot protect the probes in the region of the secondary structure. Perhaps the most surprising results bear on the two-hit model of retinoblastoma (1, 2). The mutations in patients 405 and 247 follow the expected pattern. RB405 is a unilateral tumor from a patient with no family history; the tumor retains both the paternal and maternal chromosome 13's (1), and presumably was induced by two independent mutations in the RB1 alleles. Ribonuclease protection detects only one of the mutations. RB247 is a tumor that retained both chromosome 13's (1, 13) from a bilaterally affected patient, who must carry one mutant RB1 allele in his germline. The detection of the mutation in both the tumor and lymphocytes is consistent with this conclusion.
However, patients 462 and 543 do not appear to follow the expected pattern of inheritance of mutations detected by RNase protection. Patient 462 inherited RB from his affected father; the tumor, RB462, was previously shown to have reduced to homozygosity for the paternal chromosome by the mechanism of mitotic recombination (21) . Therefore, we expected the mutation detected in RB462 to be the germline mutation inherited from the father. The absence of detectable mutant transcripts in normal cells of patient 462 or his father seems inconsistent with the pattern of inheritance, especially since the similar abnormality of RB247 was detectable in EBV247. The bilaterally affected patient 543 must also carry a germline mutation in the RB1 gene. RB543 reduced to homozygosity for chromosome 13 RFLP probes, including two within 4.7R (12, 13). RB543 was different from the other tumors in that it lacked a fiully protected band and showed only two mutant bands, the sum of which equaled the fiully protected band normally seen (Fig.  2B) . If the mutation detected by RNase protection arose before the development of homozygosity of chromosome 13, consist- 
